A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase

Sponsor

GlaxoSmithKline (Industry)

Overall Status

Completed

CT.gov ID

NCT00528281

Collaborator

(none)

Enrollment

Locations

Arm

20.2

Actual Duration (Months)

3.6

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase II study is a single-arm, two-stage, multicentre study to determine the clinical activity of lapatinib in combination with pemetrexed in patients with Non-Small Cell Lung Cancer (NSCLC) who have received one prior cytotoxic chemotherapy regimen. There will be a short safety run in portion of the study to determine the optimal treatment regimen (OTR) for the combination, since these two drugs have not previously been used together.

Approximately 27 patients will be enrolled into the first stage of the study and if sufficient responses are seen an additional 27 patients will be enrolled into the second stage giving an overall evaluable patient number of 54. Patients will be treated with pemetrexed plus lapatinib at the determined OTR to disease progression, death or withdrawal from the study treatment for any reason.

Safety and efficacy assessments will be performed on all patients at 6-week intervals, as well as at the end of treatment. Patients withdrawn from study treatment with stable disease will be assessed every 6 weeks until progression. Thereafter, patients will be followed for survival at approximately 12-week intervals until death or to a maximum of 5 years after last patient is enrolled, whichever comes first.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer, Non-Small Cell	Drug: Lapatinib Drug: Pemetrexed	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

18 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Single-arm, Two-stage Phase II Study of Lapatinib and Pemetrexed in the Second Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Actual Study Start Date :

Sep 20, 2007

Actual Primary Completion Date :

May 27, 2009

Actual Study Completion Date :

May 27, 2009

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Lapatinib + pemetrexed This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.	Drug: Lapatinib Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2. Drug: Pemetrexed Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.

Arm

Intervention/Treatment

Experimental: Lapatinib + pemetrexed

This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.

Drug: Lapatinib

Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.

Drug: Pemetrexed

Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.

Outcome Measures

Primary Outcome Measures

OTR of the combination of lapatinib and pemetrexed []

Secondary Outcome Measures

anti-tumour activity of lapatinib in terms of overall response rate []
anti-tumour activity of lapatinib in terms of duration of response, time to response, time to progression, overall survival []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

INCLUSION CRITERIA:

Signed informed consent;
Patients must be 18 years old;
Subjects must have stage IIIB or IV NSCLC .
Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;
Life expectancy of 12 weeks;
Have adequate organ function baseline laboratory values for inclusion;

EXCLUSION CRITERIA:

History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
Known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated CNS metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment.
Peripheral neuropathy of grade 3 or higher;
Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU prodrug.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	GSK Investigational Site	Heidelberg	Baden-Wuerttemberg	Germany	69126
2	GSK Investigational Site	Grosshansdorf	Schleswig-Holstein	Germany	22927
3	GSK Investigational Site	Orbassano (TO)	Piemonte	Italy	10043
4	GSK Investigational Site	Poznan		Poland	60-569
5	GSK Investigational Site	Newcastle upon Tyne		United Kingdom	NE7 7DN